50 results on '"Jaschinski, Frank"'
Search Results
2. Strong single-agent and PD-1/PD-L1 combination antitumor activity of antisense oligonucleotides suppressing Neuropilin 1 expression.
3. Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides.
4. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines
5. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
6. Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro
7. 881 Knockdown of neuropilin-1 by third generation antisense oligonucleotides has strong antitumor activity that can be further increased by combination with immune checkpoint inhibitors
8. Identification of paired-related Homeobox Protein 1 as a key mesenchymal transcription factor in pulmonary fibrosis
9. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice
10. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
11. Supplementary Information from Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis
12. Supplementary Material and Methods from Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis
13. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
14. Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression
15. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression
16. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
17. 434 Targeting the expression of Neuropilin-1 by locked nucleic acid modified antisense oligonucleotides results in potent anti-tumor activity in vivo
18. ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy
19. Abstract 4149: Knock-down of Neuropilin-1 by locked nucleic acid antisense oligonucleotides facilitates cancer immune control
20. ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy
21. Investigation of the Activity of Antisense Oligonucleotides Targeting Multiple Genes by RNA-Sequencing
22. CHOP-ASO Ameliorates Glomerular and Tubular Damage on Top of ACE Inhibition in Diabetic Kidney Disease
23. Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors
24. Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis
25. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines
26. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
27. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation
28. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
29. Additional file 5: of Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
30. Additional file 4: of Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
31. Additional file 2: of Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
32. Additional file 3: of Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
33. Additional file 1: of Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
34. Insulin receptor substrates 1 and 2 but not Shc can activate the insulin receptor independent of insulin and induce proliferation in CHO-IR cells
35. Changes in myosin heavy chain mRNA and protein isoforms of rat muscle during forced contractile activity
36. Abstract 5021: LNAplusTMantisense oligonucleotides targeting CD39 and CD73 have potent anti-tumor activity by modulating immunosuppressive tumor microenvironment
37. Abstract 3275: Inhibition of ER-stress factor C/EBP homologous protein (Chop) with LNAplus™ antisense-oligonucleotides to improve immunotherapy of cancer
38. Abstract 5909: Inhibition of Cd39 and Cd73 by 3rd-generation antisense oligonucleotides to improve immunity against tumors
39. TGF-β isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity
40. Abstract 3126: Renca RCC syngeneic model to evaluate efficacy of novel antisense oligonucleotides targeting TGF-β isoforms
41. Abstract 716: ASPH_0047: a potent and selective antisense oligonucleotide-targeting transforming growth factor beta 2 (TGF-β2)
42. Abstract 717: Novel potent antisense oligonucleotides targeting transforming growth factor beta1 (TGF-β1)
43. Preclinical profile of ASPH_0047, a potent and selective antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2).
44. Abstract 2362: Targeted suppression of TGF-beta2 by trabedersen (AP 12009) in an orthotopic xenograft melanoma mouse model
45. The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2
46. Sequential increases in capillarization and mitochondrial enzymes in low-frequency-stimulated rabbit muscle
47. The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-2
48. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
49. TGF-ß isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity.
50. Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.